Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.63 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.63 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | CTSB | P07858 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29741465 | 1.00 | MAPT (0.81) | MAPTALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL28535272 | 0.90 | MAPT (0.79) | MAPTALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL29741464 | 0.90 | MAPT (0.79) | MAPTALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL28512817 | 0.90 | MAPT (1.00) | MAPTALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL5449804 | 0.85 | ALDH1A1 (0.67) | MAPTALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL5440898 | 0.85 | CTSB (0.67) | MAPTALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2711827 | 0.81 | CTSB (0.75) | MAPTALDH1A1SMN1; SMN2HTTTNNI3 | |
| SCHEMBL24701133 | 0.78 | MTOR (0.83) | MAPTALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL4878641 | 0.77 | MAPT (1.00) | MAPTALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL28710430 | 0.77 | NCF1 (0.58) | MAPTALDH1A1KDM4EMTORLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936620-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | claimed |
| US-20030166647-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | claimed |
| CN-112390751-B | Toll-like receptor-7 small molecule inhibitor and preparation method thereof | 清华大学 | 2022-07-05 | — | — | CN | disclosed |
| CN-112390751-A | Toll-like receptor-7 small molecule inhibitor and preparation method thereof | 清华大学 | 2021-02-23 | — | — | CN | disclosed |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | disclosed |
| US-8404747-B2 | Compositions and methods for modulating interaction between polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-20050239833-A1 | Compositions and methods for modulating interaction between polypeptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2005-10-27 | — | — | US | disclosed |
| US-6936620-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20030166647-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239833-A1 | Compositions and methods for modulating interaction between polypeptides | IAPP, SERPINA6, SERPINA2 | MAPT 2215/4885ALDH1A1 4852/4885KMT2A 4744/4885 |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | IAPP, SERPINA6, SERPINA2 | MAPT 2215/4885ALDH1A1 4852/4885KMT2A 4744/4885 |
| US-20030166647-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | TNF, MMP1, ADAMTS1 | MAPT 1837/4885ALDH1A1 382/4885KMT2A 2725/4885 |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | IAPP, SERPINA6, SERPINA2 | MAPT 2215/4885ALDH1A1 4852/4885KMT2A 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.